Given that cholesterol abundance in the cell membrane could maintain the surface levels of ErbB2, we speculated that the inhibitory effects of the cholesterol-lowering drug lovastatin against ErbB2-positive breast cancer cells might be associated with compromised cell membrane expression of ErbB2 and the resultant attenuation of downstream signal transmission. Here, ERBB2 is linked to breast cancer.